[ASEAN] Regulatory Insights on Zepzelca, Resolution Planning & Rule VI Updates

This episode of Carver's ASEAN Regulatory Updates delves into significant regulatory changes affecting diverse sectors including pharmaceuticals, financial market infrastructures, and digital market competition.

Key highlights include Singapore’s Monetary Authority introducing a Consultation Paper that mandates expanded recovery and resolution planning requirements along with statutory bail-in powers for capital market infrastructures, marking a substantial step towards international alignment in financial stability frameworks.

Additionally, the Health Sciences Authority’s intensified enforcement against illegal health products and reclassification of etomidate as a Class C drug underline increased regulatory vigilance on public health safety in Singapore.

In the Philippines, regulatory input is sought under Rule VI of Republic Act No. 12234 to foster competition and efficient use of digital infrastructure, signaling important market and compliance implications.

For more information, visit the Carver Agents website.

Articles mentioned:

1. Basel III monitoring report
2. Summary report on authorisation – Zepzelca®
3. Consultation Paper on Notice and Guidelines for Recovery and Resolution Planning and Enhancement of Resolution Powers for Capital Market Infrastructures
4. Indonesia: [Government of Indonesia] mulls lifting deficit cap amid high oil price
5. HSA Seized Over 1 Million Illegal Health Products and Removed More Than 2,300 Online Listings in 2025

1. קול קורא לשת"פ קרן סינגפור-ישראל (SIIRD) בתחום ערים חכמות

1. Philippines - Ceramic tiles
2. UN convention on judicial sale of ships signed in Beijing
3. Terminologies for Categorized Adverse Event Reporting (AER): terms, terminology and codes
4. Call For Inputs: Access List